IQ's First Decade: Reflections from IQ Leaders

The IQ Consortium marks its 10th anniversary with a year-long series entitled IQ's First Decade: Reflections from IQ Leaders. In this series, IQ leaders from 2010 to present share their perspectives on the impact brought to the global pharmaceutical industry by IQ initiatives and the value of the IQ consortium’s collaborative environment. 


Terry Tougas, PhD

TERRY TOUGAS, PhD  
IQ Chair (2010-2012)

Highly Distinguished Research Fellow
Boehringer Ingelheim (Ret.)

Lewis Kinter, PhD

LEWIS KINTER, PhD, DABT, FATS   
IQ Chair (2012-2014)
Senior Director, Regulatory Toxicology
AstraZeneca (Ret.)

MARGARET FAUL, PhD
IQ Chair (2021-2023)

Vice President, Drug Product Technologies 
Amgen

Michael Garvin, PhD

MICHAEL GARVIN, PharmD
IQ Board of Directors (2014-present)

Senior Director, Regulatory Policy
AstraZeneca

Douglas Keller, PhD

DOUG KELLER, PhD
IQ Board of Directors (2010-2020)

Global Head for Development Projects, Preclinical Safety
Sanofi (Ret.)

 

Nancy Agrawal, PhD

NANCY AGRAWAL, PhD
IQ Translational and ADME Sciences Leadership Group (2013-present)

Vice President, Pharmacokinetics, Pharmacodynamics,
Drug Metabolism (PPDM)
Merck & Co., Inc.

Akintunde

TUNDE BELLO, PhD
IQ Clinical Pharmacology Leadership Group (2012-present)
Vice President, Clinical Pharmacology and Pharmacometrics
Bristol-Myers Squibb

Timothy JN Watson, PhD 

TIM WATSON, PhD
IQ VICE CHAIR (2021-2023)
Executive Director/Leader of the Global CMC Advisory Office
Pfizer